Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 109,992 shares at $7.19 ($784K) on 2023-08-01, disclosed to the SEC on 2023-08-03.
Scheduled sale ($784k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.19 | 18,715 | $135K | 17.2% |
| 2 | $7.19 | 18,715 | $135K | 17.2% |
| 3 | $7.09 | 36,281 | $257K | 32.8% |
| 4 | $7.09 | 36,281 | $257K | 32.8% |
| Total | $7.12 avg | 109,992 | $784K | 100% |
| Filing → |
| SPRY | SELL | 2025-02-04 | $616K | — | Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |